Science Explorer Interactive view Map
Topic · Cancer Research

Protease and Inhibitor Mechanisms

Protease and Inhibitor Mechanisms is a research topic within Cancer Research. Science Explorer counts 38k research works in it since 1950. 20.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the multifaceted roles of matrix metalloproteinases (MMPs) in cancer progression, angiogenesis, inflammation regulation, and extracellular matrix remodeling. It also delves into the potential of MMPs as therapeutic targets for cancer therapy and their involvement in various physiological processes such as cell signaling and tissue remodeling.

  • Matrix Metalloproteinases
  • Tissue Inhibitors of Metalloproteinases
  • Cancer Progression
  • Angiogenesis
  • Extracellular Matrix Remodeling
  • Protease Inhibition
  • Inflammation Regulation
  • Cell Signaling
  • Metastasis
  • Extracellular Matrix
Research works
38k
fractional, since 1950
In the world top 10%
7.6k
per year above
Top-10% rate
20.0%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
-19%
the tick is no change

Which countries lead Protease and Inhibitor Mechanisms research?

By volume, China and the United States publish the most (861 and 536 works in 2022–2025).

By volume, 2022–2025

  1. 1 China 861 works
  2. 2 United States 536 works
  3. 3 India 153 works
  4. 4 Germany 142 works
  5. 5 Japan 122 works
  6. 6 United Kingdom 97 works
  7. 7 Italy 88 works
  8. 8 Spain 77 works
  9. 9 Türkiye 69 works
  10. 10 France 68 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 38.9%United States: 24.2%India: 6.9%Germany: 6.4%6 others listed: 23.6%39%largest
China861 · 38.9%United States536 · 24.2%India153 · 6.9%Germany142 · 6.4%6 others listed522 · 23.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Protease and Inhibitor Mechanisms research?

By volume in 2022–2025, Sichuan University publishes the most Protease and Inhibitor Mechanisms research, followed by Royal College of Surgeons in Ireland and Nanjing Medical University.

By volume, 2022–2025

  1. 1 Sichuan University China 14 works
  2. 2 Royal College of Surgeons in Ireland Ireland 12 works
  3. 3 Nanjing Medical University China 11 works
  4. 4 Nordic Bioscience (Denmark) Denmark 11 works
  5. 5 Shanghai Jiao Tong University China 10 works
  6. 6 Chinese Academy of Medical Sciences & Peking Union Medical College China 10 works
  7. 7 University of California San Diego United States 10 works
  8. 8 Sun Yat-sen University China 9 works
  9. 9 Mashhad University of Medical Sciences Iran 9 works
  10. 10 Peking University China 9 works

Where is Protease and Inhibitor Mechanisms research done?

The largest centres of Protease and Inhibitor Mechanisms research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Dublin.

Largest cities, 2022–2025

  1. 1 Beijing China 87 works
  2. 2 Shanghai China 75 works
  3. 3 Guangzhou China 62 works
  4. 4 Nanjing China 37 works
  5. 5 Wuhan China 32 works
  6. 6 Chengdu China 32 works
  7. 7 Tokyo Japan 30 works
  8. 8 Paris France 30 works
  9. 9 London United Kingdom 26 works
  10. 10 Moscow Russia 26 works

Where it is the local speciality

  1. DublinIE · 22.6 works4.6×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Protease and Inhibitor Mechanisms than the world average.

See Protease and Inhibitor Mechanisms on the map

Where is the best place to study Protease and Inhibitor Mechanisms?

Among universities, judged by research, Mashhad University of Medical Sciences, Nanjing Medical University and Royal College of Surgeons in Ireland score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 25.88%fractional works in this node (log) →share in the world top 10% →Mashhad University of Medical Sciences: 9, 27.3%Nanjing Medical University: 11, 23.9%Royal College of Surgeons in Ireland: 12, 5.0%Sichuan University: 14, 30.8%Chinese Academy of Medical Sciences & Peking Union Medical College: 10, 34.7%Shanghai Jiao Tong University: 10, 33.7%Capital Medical University: 9, 30.8%University of California San Diego: 10, 23.4%Peking University: 9, 27.9%Sun Yat-sen University: 9, 21.3%Sichuan UniversityMashhad University o…Nanjing Medical Univ…Royal College of Sur…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1Mashhad University of Medical Sciences Iran 67.627.3%12.2×9 +195.1%
2Nanjing Medical University China 52.723.9%7.3×11 +3.8%
3Royal College of Surgeons in Ireland Ireland 52.15.0%48.8×12 -13.9%
4Sichuan University China 51.730.8%2.6×14 -23.7%
5Chinese Academy of Medical Sciences & Peking Union Medical College China 48.034.7%3.5×10 -14.7%
6Shanghai Jiao Tong University China 43.933.7%1.6×10 +0.6%
7Capital Medical University China 40.130.8%4.9×9 -31.2%
8University of California San Diego United States 36.523.4%3.8×10 -47.2%
9Peking University China 31.527.9%1.8×9 -15.0%
10Sun Yat-sen University China 26.421.3%1.9×9 -13.9%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Protease and Inhibitor Mechanisms research growing?

Output in 2018–2022 was 19% lower than in 2013–2017, peaking in 2012.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.